Cryoballoon Ablation Versus Medical Therapy in Patients With Heart Failure and Atrial Fibrillation

Heart Failure Clinical Trial

— RACE-8-HF  

Official title:

CRyoballoon Ablation Versus mediCal thErapy in Patients With Heart Failure and Atrial Fibrillation: A Multicenter Randomized Clinical Trial, the RACE-8-HF Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04342832
• Other study ID #: NL71710.068.19
• Status: Recruiting
• Phase: N/A
• Start date: July 16, 2020
• Est. completion date: September 1, 2024

Study information

• Verified date: March 2021
• Source: Maastricht University
• Contact: Dominique Verhaert, MD
• Phone: +31 24 30 92470
• Email: dominique.verhaert[@]radboudumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale:

Atrial fibrillation (AF) and heart failure (HF) can cause each other and sustain each other. Combined, the two diseases negatively influence each other's prognosis and lead to higher mortality. Studies in HF patients in which the AF burden is reduced by AF ablation show promising results toward improved prognosis, but so far only one randomized trial is conducted that focused on major clinical endpoints. As the selected patients in this trial were not representative for the entire population and its ablation method varied from patient to patient, it is the aim of the present study to confirm that early invasive therapy consisting of a strict pulmonary vein isolation (PVI) protocol using cryoballoon therapy has positive effects on hard clinical endpoints in a wider variety of patients in the HF population.

Furthermore, there are no studies which compare cost-effectiveness of an early invasive strategy in this patient category. The investigators expect that avoided hospitalizations and healthcare resource utilizations lead to lower costs in the AF ablation group, despite initial higher costs of the procedure.

Objective:

To compare outcome and cost-effectiveness of early AF ablation by PVI using cryoballoon therapy with standard (medical) therapy in patients with heart failure with reduced ejection fraction.

Study design:

Multicenter, randomized, open label clinical trial.

Study population:

Symptomatic adult patients with heart failure with reduced ejection fraction (<40%) and paroxysmal or persistent AF.

Intervention:

AF ablation (PVI) using cryoballoon therapy.

Outcome measures:

The primary endpoint is a combined endpoint of all-cause mortality, unplanned cardiovascular hospitalization, and stroke (time-to-event analysis).

Secondary endpoints of the trial are:

• A combined endpoint of mortality, number of unplanned cardiovascular hospitalizations, and stroke (recurrent-event analysis);

• A hierarchical endpoint of mortality, unplanned cardiovascular hospitalizations, stroke, and HF complaints;

• Cost-effectiveness. Key exploratory endpoints include individual components of the combined endpoints, days alive out of the hospital, hospitalizations for heart failure, recurrence of atrial arrhythmia, and quality of life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: September 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients aged 18-80;

• HF with ejection fraction <40%, as assessed by recent (<6 months) echocardiography or cardiovascular magnetic resonance imaging (CMR);

• AF, documented on standard ECG or Holter monitoring;

• Eligible for both treatment arms;

• Signed and dated informed consent prior to admission to the trial.

Exclusion Criteria:

• End-stage heart failure: NYHA class IV, patients on waiting list for cardiac transplant and/or left ventricular assist device;

• Long-standing (> 1 year) persistent or permanent AF;

• Previous pulmonary vein isolation or surgical ablation;

• Left atrial diameter =60 mm or left atrial volume index =50 ml/m2;

• Impaired renal function, defined as estimated glomerular filtration rate (eGFR) =25 ml/min/1.73m2;

• Recent (<90 days) acute coronary syndrome, cardiac intervention1, or stroke/transient ischemic attack (TIA);

• Planned or expected cardiac surgery in the following year;

• Active infectious disease or malignancy;

• Women who are pregnant or planning to become pregnant during the trial;

• Contraindication for cryoballoon ablation or other condition that may prevent subjects from adhering to the trial protocol, in the opinion of the investigator.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Heart Failure
• Heart Failure With Reduced Ejection Fraction
• Heart Failure, Systolic

Intervention

Procedure:
• Cryoballoon ablation
If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.

Locations

Country	Name	City	State
Netherlands	Maastricht UMC+	Maastricht	Limburg
Netherlands	Radboudumc	Nijmegen	Gelderland

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite of all-cause mortality, unplanned cardiovascular hospitalizations and stroke (time-to-event analysis)		Study duration (1-5 years, expected median follow-up duration 2 years)
Secondary	Combined endpoint of all-cause mortality		Study duration (1-5 years, expected median follow-up duration 2 years)
Secondary	Total number of unplanned cardiovascular hospitalizations and stroke (recurrent-event analysis)		Study duration (1-5 years, expected median follow-up duration 2 years)
Secondary	Hierarchal endpoint of all-cause mortality, unplanned cardiovascular hospitalizations, stroke and change in heart failure complaints (hierarchical endpoint analysis)		Study duration (1-5 years, expected median follow-up duration 2 years)
Secondary	Cost-effectiveness		Study duration (1-5 years, expected median follow-up duration 2 years)
Secondary	Budget impact		Study duration (1-5 years, expected median follow-up duration 2 years)